LFX/PGB
Phase 2Small molecule
LFX/PGB is one of 4 small molecule programs targeting Opioid Withdrawal. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Opioid Withdrawal
#DrugCompanyPhaseTrials
1Atarax
PfizerPreclinical
BXCL501
BBioXcel Therapeutics Inc
Phase 2
Aloxi
AAvyxa
Preclinical
LFX/PGB
UUniversity of Pennsylvania
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LFX/PGB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Pennsylvania